Celldex Therapeutics (CLDX) Competitors

Celldex Therapeutics (NASDAQ:CLDX) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, community ranking, risk, dividends, earnings and valuation.

Is CLDX or ALKS more profitable?

Alkermes has a net margin of 23.57% compared to Celldex Therapeutics' net margin of -1,544.32%. Alkermes' return on equity of 30.80% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	-1,544.32%	-19.75%	-18.86%
Alkermes	23.57%	30.80%	19.09%

Does the media favor CLDX or ALKS?

In the previous week, Celldex Therapeutics had 4 more articles in the media than Alkermes. MarketBeat recorded 14 mentions for Celldex Therapeutics and 10 mentions for Alkermes. Celldex Therapeutics' average media sentiment score of 1.04 beat Alkermes' score of 0.87 indicating that Celldex Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celldex Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alkermes	6 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has higher earnings and valuation, CLDX or ALKS?

Alkermes has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$7.56M	178.72	-$141.43M	-$2.70	-7.54
Alkermes	$1.51B	3.35	$367.07M	$2.09	14.73

Do analysts recommend CLDX or ALKS?

Celldex Therapeutics currently has a consensus target price of $53.90, indicating a potential upside of 164.86%. Alkermes has a consensus target price of $38.85, indicating a potential upside of 26.21%. Given Celldex Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Celldex Therapeutics is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.90
Alkermes	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.77

Do institutionals & insiders hold more shares of CLDX or ALKS?

95.2% of Alkermes shares are owned by institutional investors. 3.8% of Celldex Therapeutics shares are owned by insiders. Comparatively, 4.4% of Alkermes shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Does the MarketBeat Community prefer CLDX or ALKS?

Alkermes received 79 more outperform votes than Celldex Therapeutics when rated by MarketBeat users. However, 75.27% of users gave Celldex Therapeutics an outperform vote while only 70.18% of users gave Alkermes an outperform vote.

Company	Underperform	Outperform
Celldex Therapeutics	Outperform Votes 627 75.27%	Underperform Votes 206 24.73%
Alkermes	Outperform Votes 706 70.18%	Underperform Votes 300 29.82%

Which has more volatility and risk, CLDX or ALKS?

Celldex Therapeutics has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500.

Summary

Alkermes beats Celldex Therapeutics on 11 of the 18 factors compared between the two stocks.